This preclinical study examined Aureobasidium pullulans SM-2001 exopolymers containing beta-1,3/1,6-glucan in mice made immunosuppressed with cyclophosphamide. The researchers administered the exopolymers orally or subcutaneously and measured thymus and spleen weights, T-cell subsets, TNF-alpha-positive cells, and splenic cytokines. Several cyclophosphamide-associated reductions were partially reversed after treatment. Because the work used an animal model, it does not establish efficacy, dosing, or safety for immunosuppression or related diseases in humans.
This 2010 preclinical study evaluated Aureobasidium pullulans SM-2001 exopolymers containing beta-1,3/1,6-glucan in a cyclophosphamide-induced immunosuppression mouse model.
Mice received the exopolymers orally or subcutaneously. The investigators measured thymus and spleen weights, T-cell subsets, TNF-alpha-positive cells, and splenic TNF-alpha, IL-1beta, and IL-10. The treatment partially countered several cyclophosphamide-associated changes.
These findings are limited to an animal model. They do not demonstrate prevention or treatment of immunosuppression, cancer, sepsis, or chemotherapy effects in humans.
Yoon HS; Kim JW; Cho HR; Moon SB; Shin HD; Yang KJ; Lee HS; Kwon YS; Ku SK. Immunomodulatory effects of Aureobasidium pullulans SM-2001 exopolymers on the cyclophosphamide-treated mice. Journal of Microbiology and Biotechnology. 2010. PMID: 20208453.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.